What does Quince Therapeutics do?

Quince Therapeutics, Inc. is a late-stage biotechnology company dedicated to developing treatments for rare diseases. Founded in 2012 and previously known as Cortexyme, Quince focuses on harnessing the power of a patient's own biology, particularly through its lead program targeting Ataxia-Telangiectasia (A-T). The company has made significant progress, including a partnership in 2018 and a successful IPO in 2019. Quince's primary product candidate is the eDSP System, an investigational therapy aimed at treating A-T, a rare pediatric neurodegenerative disorder. The company is currently conducting a pivotal Phase 3 trial, known as the NEAT trial, to assess the safety and efficacy of the eDSP System. This trial involves 105 participants, with results expected in early 2026. The U.S. FDA has granted Fast Track designation to the eDSP System, underscoring the urgent need for effective treatments in this area.